Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 6/20 | 0.46 |
| ▸ | PSMB9 | P28065 | 6/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 6/20 | 0.46 |
| ▸ | PSMB10 | P40306 | 4/20 | 0.46 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.46 |
| ▸ | PSMB8 | P28062 | 5/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2906422 | 0.87 | OPRD1 (0.44) | PSMB8MMEACECPA1ACE2 | |
| SCHEMBL2901655 | 0.84 | OPRD1 (0.44) | PSMB8MMEACECPA1ACE2 | |
| SCHEMBL2906563 | 0.81 | OPRD1 (0.41) | PSMB8MMEACECPA1ACE2 | |
| SCHEMBL2901690 | 0.76 | OPRD1 (0.42) | PSMB8MMEACECPA1ACE2 | |
| SCHEMBL2906899 | 0.76 | OPRD1 (0.45) | MMEACECPA1ACE2OPRD1 | |
| SCHEMBL11760152 | 0.72 | LNPEP (0.59) | PSMB1PSMB9PSMB5PSMB10PSMB2 | |
| SCHEMBL29839243 | 0.71 | LTA4H (0.55) | MMEOPRD1 | |
| SCHEMBL11598821 | 0.68 | CTSC (0.52) | PPARGLNPEP | |
| SCHEMBL11670615 | 0.68 | ERAP2 (0.61) | PSMB1PSMB9PSMB5PSMB10PSMB2 | |
| SCHEMBL30631019 | 0.68 | PSMB1 (0.61) | PSMB1PSMB9PSMB5PSMB10PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2239270-A2 | Low molecular weight peptide derivatives as inhibitors of the Laminin/Nidogen interaction | Sanofi-Aventis Deutschland GmbH (DE) | 2010-10-13 | — | — | EP | disclosed |
| EP-1845106-B1 | Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-08-11 | — | — | EP | disclosed |
| EP-1845106-A1 | Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction | Sanofi-Aventis Deutschland GmbH (DE) | 2007-10-17 | — | — | EP | disclosed |
| EP-1157040-B1 | LOW MOLECULAR WEIGHT PEPTIDE DERIVATIVES AS INHIBITORS OF THE LAMININ/NIDOGEN INTERACTION | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-08-22 | — | — | EP | disclosed |
| US-6365572-B1 | FOR THERAPY OF DISEASES RELATED TO INCREASED OR UNWANTED SYNTHESIS OF BASEMENT MEMBRANES SUCH AS DIABETES MELLITUS; ATHEROSCLEROSIS; CANCER; DIABETIC RETINOPATHIA; FIBROPLASIA RETROLENTALIS; OR PSORIASIS, RHEUMATOIC ARTHRITIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-02 | — | — | US | disclosed |